Century Therapeutics Inc (IPSC) - Total Liabilities
Based on the latest financial reports, Century Therapeutics Inc (IPSC) has total liabilities worth $54.66 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Century Therapeutics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Century Therapeutics Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Century Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Century Therapeutics Inc (IPSC) total assets.
Century Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Century Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Energy One Ltd
AU:EOL
|
Australia | AU$37.62 Million |
|
Unggul Indah Cahaya Tbk
JK:UNIC
|
Indonesia | Rp48.28 Million |
|
AMTD Digital Inc.
NYSE:HKD
|
USA | $351.70 Million |
|
EuroHold Bulgaria AD
WAR:EHG
|
Poland | zł1.48 Billion |
|
Nanjing OLO Home Furnishing
SHG:603326
|
China | CN¥813.52 Million |
|
BRASI.CIA BRAS.D.PROP.ADR
F:52BA
|
Germany | €1.78 Billion |
|
Dadelo S.A.
WAR:DAD
|
Poland | zł309.55 Million |
|
Bakkt Holdings Inc
NYSE:BKKT
|
USA | $42.50 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Century Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Century Therapeutics Inc (IPSC) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Century Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Century Therapeutics Inc (2015–2025)
The table below shows the annual total liabilities of Century Therapeutics Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $64.77 Million | -66.24% |
| 2024-12-31 | $191.85 Million | +9.04% |
| 2023-12-31 | $175.94 Million | -4.28% |
| 2022-12-31 | $183.81 Million | +346.81% |
| 2021-12-31 | $41.14 Million | -80.70% |
| 2020-12-31 | $213.19 Million | +16.65% |
| 2019-12-31 | $182.75 Million | -68.25% |
| 2016-12-31 | $575.54 Million | +18.67% |
| 2015-12-31 | $484.99 Million | -- |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more